Gene Solutions at ESMO ASIA 2024: Empowering Cancer Care with Multi-Dimensional Genomics & AI

This year, ESMO Asia brought together over 4,000 passionate oncology experts, creating an incredible opportunity for collaboration and innovation. It wasn’t just a gathering; it was a moment to share knowledge, exchange ideas, and work towards a common goal: “Advancing the fight against cancer across the Asia-Pacific.” 

At our exhibition site, Gene Solutions presented our key products: SPOT-MAS (Multi-cancer early detection) and K-TRACK (Genomic Profiling & Molecular Residual Disease), alongside two CAP-Accredited laboratories in Singapore and Vietnam. Our mission is to empower cancer care by leveraging the combination of genomics and artificial intelligence. 

 

Our area became a hub of connection, welcoming hundreds of medical oncologists, surgeons, scientists, and pharmacists from Australia, India, China, Hong Kong SAR, Korea, Taiwan, and other Southeast Asian countries. The groundbreaking ctDNA technology we introduced generated significant interest and promises to revolutionize early detection and personalized treatment strategies.   

What made this experience truly special were the conversations. Doctors and professors from around the world shared their thoughts on how these tools could help in real life. They offered advice on clinical studies and discussed the challenges of treating lung, colorectal, breast, and liver cancers, providing insights that were both thoughtful and inspiring.

 

It was inspiring to see so many people working together, united by a shared purpose. The stories we heard, the ideas exchanged, and the bonds formed remind us that progress doesn’t happen in isolation. It’s built through connection, collaboration, and a steadfast belief in a better future. 

As we look back, we are filled with gratitude for every interaction, every shared story, and every moment of connection. We’re deeply thankful for everyone who visited us and shared their wisdom. Together, we are building a brighter future in cancer care—one step, one conversation, and one idea at a time. The fight against cancer is long and challenging, but as we witnessed at ESMO Asia 2024, it is a fight that we are all in together. 

Stay in touch with us in the coming days to dive into our oral sessions and poster awards from this year’s congress. 

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More